6109 – Influenza Antigen Quick

Highlights

• Use of highly specific monoclonal antibodies for the rapid detection of Influenza A and B virus antigens in human nasal and nasopharyngeal specimens (swab, wash, and aspirate)
• Supports the diagnosis of influenza virus infections in combination with clinical and laboratory findings
• Ready-to-use test strips with color-coded antibodies and integrated control line for reliable results
• Manual handling optimized for professional in vitro diagnostic use
• Provides clear visual results within minutes, enabling fast decision-making in clinical settings
• High sensitivity and specificity for detection of both Influenza A (H1N1 and H3N2 subtypes) and Influenza B
• Non-invasive testing with direct antigen detection, requiring no specialized instruments
• Includes complete kit components: 25 test strips, sample diluent, and instructions for use
• Flexible sample handling: freshly collected nasal or nasopharyngeal specimens recommended
• Suitable for routine laboratory workflows
• CE marked

Intended Use

The Influenza Antigen Quick is a qualitative rapid immunoassay for detecting Influenza A and B virus antigens in human nasal and nasopharyngeal specimens, including swabs, washes, and aspirates. The test provides a reliable aid in the diagnosis of influenza infections, delivering timely information to support clinical evaluation and laboratory findings. Its simple, manual procedure is optimized for professional in vitro diagnostic use, producing rapid results without requiring specialized instruments or complex laboratory equipment. The assay enables early detection of viral antigens, supporting prompt clinical decision-making and facilitating appropriate patient management. The immunoassay is designed for manual professional in vitro diagnostic use.

Diagnostic Relevance

Influenza viruses primarily infect the upper respiratory tract, including the nose, throat, and bronchi, and may occasionally extend to the lungs. Infection typically presents with sudden onset of high fever, myalgia, headache, malaise, non-productive cough, sore throat, and rhinitis, and usually resolves within one to two weeks in otherwise healthy individuals. The virus poses a significant risk to young children, older adults, and patients with underlying conditions such as lung disease, diabetes, cardiovascular disease, or immunocompromised states, where severe complications, pneumonia, or even death may occur.

The Influenza viruses are characterized by two surface proteins, haemagglutinin (H) and neuraminidase (N), which define viral subtypes and influence pathogenicity and immune recognition. Currently circulating human influenza viruses are classified into two main groups: A and B. Influenza A viruses include clinically significant subtypes, such as A (H1N1) and A (H3N2), with H3N2 historically associated with higher morbidity and mortality. Influenza B viruses are generally less variable but contribute significantly to seasonal outbreaks. Rapid identification of the specific viral antigens allows healthcare providers to differentiate between influenza types, guide appropriate antiviral therapy, and implement timely infection control measures.